DJ-1 in the Neuro-cutaneous Aging Axis: Unifying Pathways of Parkinson's Disease Neurodegeneration, Progression, and Redox-Based Therapeutic Strategies for Healthy Longevity.

Sleep and circadian disturbances precede motor symptoms in Parkinson's disease (PD), acting as early neurodegeneration indicators. Disrupted rhythms, mitochondrial dysfunction, neuroinflammation, and neurotransmitter imbalance create a self-reinforcing cycle that accelerates progression. DJ-1 (PARK7), a redox-sensitive protein, provides central neuroprotection by preserving mitochondrial integrity, mitigating oxidative stress, and curbing neuroinflammation. DJ-1 loss or mutation weakens antioxidant defences, promotes α-synuclein aggregation, and worsens dopaminergic neuron loss, positioning it as a key biomarker and therapeutic target. Oxidative stress, mitochondrial impairment, chronic inflammation, and telomere attrition link neurodegeneration to systemic and skin aging via a "neuro-cutaneous aging axis." Similar mechanisms include mitochondrial dysfunction, ferroptosis, and redox imbalance energy Alzheimer's cognitive decline. Chronotherapy, NRF2 activators, phytochemicals, nanozymes, and postbiotics offer promise in restoring redox balance and halting progression. Telomere dysfunction and genomic instability further connect neural and skin aging, modulated by environment, diet, and lifestyle. Micro physiological systems, predictive analytics, and personalized medicine enhance mechanistic insights and therapy development. Targeting interconnected pathways of redox regulation, mitochondrial function, proteostasis, and telomere maintenance provides a unified approach to combat neurodegeneration and aging. DJ-1-focused therapies, paired with antioxidants and mitochondrial interventions, hold strong potential for disease modification and healthy aging.